Clinical Efficacy of Thalidomide in the Treatment of Mucocutaneous Lesions of Behçet Disease_West China Medical Journal

Authors：

LIU Yixin ¹ ,  LI Xinyi. ²

1. Department of Geriatric Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China; 2. Department of Internal Medicine, No. 363 Hospital of Chengdu, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

LI Xinyi., Email: onlybush@yeah.net

Keywords：

白塞病; 黏膜潰瘍; 沙利度胺

DOI：

10.7507/1002-0179.20130062

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　了解沙利度胺對白塞病黏膜損害的療效。方法　對2002年1月－2008年12月間61例白塞病患者的臨床資料進行回顧性研究，所有納入患者均無重要內臟器官的損害。沙利度胺治療劑量100 mg/d，治療療程12周，以后逐步減量。結果　48例完全緩解（在治療期間無口腔及外生殖器潰瘍），但停藥后潰瘍復發。7例出現上下肢體麻木感，停藥后麻木感消失。結論　沙利度胺對白塞病的口腔及外生殖器潰瘍治療有效，100 mg/d的治療劑量合適。

Citation： LIU Yixin,LI Xinyi.. Clinical Efficacy of Thalidomide in the Treatment of Mucocutaneous Lesions of Behçet Disease. West China Medical Journal, 2013, 28(2): 192-194. doi: 10.7507/1002-0179.20130062 Copy

1.	Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease[J]. Lancet, 1990, 335(8697): 1078-1080.
2.	Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet’s disease[J]. Semin Arthritis Rheum, 1998, 27(4): 197-217.
3.	Alpsoy E, Er H, Durusoy C, et al. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study[J]. Arch Dermatol, 1999, 135(5): 529-532.
4.	D’Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis[J]. Proc Natl Acad Sci USA, 1994, 91(9): 4082-4085.
5.	Stambe C, Wicks IP. TNFalpha and response of treatment-resistant adult-onset Still’s disease to thalidomide[J]. Lancet, 1998, 352(9127): 544-545.
6.	Keenan RJ, Eiras G, Burckart GJ, et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506[J]. Transplantation, 1991, 52(5): 908-910.
7.	Nogueira AC, Neubert R, Helge H, et al. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells[J]. Life Sci, 1994, 55(2): 77-92.
8.	Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity[J]. Science, 2010, 327(5971):1345-1350.
9.	杜趁香，王焱. 沙利度胺抗腫瘤作用的研究進展[J]. 河南科技大學學報(醫學版), 2009，1(27): 79-80.
10.	Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet’s syndrome. A randomized, double-blind, placebo-controlled trial[J]. Ann Intern Med, 1998, 128(6): 443-450.
11.	Ehrlich GE. Behçet’s disease and the emergence of thalidomide[J]. Ann Intern Med, 1998, 128(6): 494-495.
12.	Wulff CH, Hoyer H, Asboe-Hansen G, et al. Development of polyneuropathy during thalidomide therapy[J]. Br J Dermatol, 1985,112(4): 475-480.

1. 　Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease[J]. Lancet, 1990, 335(8697): 1078-1080.
2. 　Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet’s disease[J]. Semin Arthritis Rheum, 1998, 27(4): 197-217.
3. 　Alpsoy E, Er H, Durusoy C, et al. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study[J]. Arch Dermatol, 1999, 135(5): 529-532.
4. 　D’Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis[J]. Proc Natl Acad Sci USA, 1994, 91(9): 4082-4085.
5. 　Stambe C, Wicks IP. TNFalpha and response of treatment-resistant adult-onset Still’s disease to thalidomide[J]. Lancet, 1998, 352(9127): 544-545.
6. 　Keenan RJ, Eiras G, Burckart GJ, et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506[J]. Transplantation, 1991, 52(5): 908-910.
7. 　Nogueira AC, Neubert R, Helge H, et al. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells[J]. Life Sci, 1994, 55(2): 77-92.
8. 　Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity[J]. Science, 2010, 327(5971):1345-1350.
9. 　杜趁香，王焱. 沙利度胺抗腫瘤作用的研究進展[J]. 河南科技大學學報(醫學版), 2009，1(27): 79-80.
10. 　Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet’s syndrome. A randomized, double-blind, placebo-controlled trial[J]. Ann Intern Med, 1998, 128(6): 443-450.
11. 　Ehrlich GE. Behçet’s disease and the emergence of thalidomide[J]. Ann Intern Med, 1998, 128(6): 494-495.
12. 　Wulff CH, Hoyer H, Asboe-Hansen G, et al. Development of polyneuropathy during thalidomide therapy[J]. Br J Dermatol, 1985,112(4): 475-480.

West China Medical Journal

Clinical Efficacy of Thalidomide in the Treatment of Mucocutaneous Lesions of Behçet Disease

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content